Seeking Alpha
Value
Profile| Send Message|
( followers)  

Interested in pharmaceutical companies? In search of companies that can manage their debt well? Do you prefer companies that can manage their long term debt? Are you after stocks that analysts are calling 'buy' or 'strong buy'? If so, you'll probably like this list.

The Debt/Equity Ratio illustrates how aggressively a company is financing its growth via debt. The more debt financing that is used in a capital structure, the more volatile earnings can become due to the additional interest expense. Should a company's potentially enhanced earnings fail to exceed the cost associated with debt financing over time, this can lead the company toward substantial trouble.

The Long Term Debt/Equity Ratio is a variation of the traditional debt-to-equity ratio; this value computes the proportion of a company's long-term debt compared to its available capital. By using this ratio, investors can identify the amount of leverage utilized by a specific company and compare it to others to help analyze the company's risk exposure. Generally, companies that finance a greater portion of their capital via debt are considered riskier than those with lower leverage ratios.

We first looked for pharmaceutical stocks. We then looked for companies that operate with little to no debt (D/E Ratio<.3). Next, we then screened for businesses that have maintained a sound long term capital structure (Long Term D/E Ratio<.1). Next, we then screened for businesses that analysts rate as "Buy" or "Strong Buy" (mean recommendation < 3). We did not screen out any market caps.

Do you think these stocks will go up in price? Use this list as a starting-off point for your own analysis.

1) Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Sector:Healthcare
Industry:Drug Manufacturers - Major
Market Cap:$134.55M
Beta:3.36

Keryx Biopharmaceuticals Inc. has a Debt/Equity Ratio of 0.00 and Long Term Debt/Equity Ratio of 0.00 and Analysts' Rating of 1.80. The short interest was 13.77% as of 05/12/2012. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. The company's products under development include KRX-0401 (perifosine), an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, as well as affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Its KRX-0401 is in Phase III clinical development stage for the treatment of refractory advanced colorectal cancer and multiple myeloma, as well as in Phase I and Phase II clinical development stages for the treatment of other tumor types.

2) Echo Therapeutics, Inc. (NASDAQ:ECTE)

Sector:Healthcare
Industry:Drug Manufacturers - Major
Market Cap:$71.85M
Beta:0.34

Echo Therapeutics, Inc. has a Debt/Equity Ratio of 0.00 and Long Term Debt/Equity Ratio of 0.00 and Analysts' Rating of 1.50. The short interest was 1.37% as of 05/12/2012. Echo Therapeutics, Inc. operates as a transdermal medical device company in the United States. The company is involved in developing Prelude SkinPrep System, which is a platform technology to allow painless skin permeation that would enable both needle-free drug delivery and analyte extraction; and Symphony tCGM System, a non-invasive, wireless, and transdermal continuous glucose monitoring system for use in hospital critical care units and for patients with diabetes. It also engages in the development of specialty pharmaceuticals based on its proprietary AzoneTS transdermal drug reformulation technology.

3) Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Sector:Healthcare
Industry:Drug Manufacturers - Major
Market Cap:$593.75M
Beta:1.49

Rigel Pharmaceuticals, Inc. has a Debt/Equity Ratio of 0.00 and Long Term Debt/Equity Ratio of 0.00 and Analysts' Rating of 1.60. The short interest was 5.75% as of 05/12/2012. Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its product development programs include R788, which completed a phase 2 clinical trial for the treatment of rheumatoid arthritis; and is in phase 2 clinical trials for B-cell lymphoma, T-cell lymphoma, immune thrombocytopenia purpura, and certain solid tumors. The company's product development programs also comprise R343, which is in phase 1b clinical trial for the treatment of asthma.

4) Ventrus Biosciences Inc. (VTUS)

Sector:Healthcare
Industry:Drug Manufacturers - Major
Market Cap:$136.34M
Beta:-

Ventrus Biosciences Inc. has a Debt/Equity Ratio of 0.00 and Long Term Debt/Equity Ratio of 0.00 and Analysts' Rating of 1.40. The short interest was 3.14% as of 05/12/2012. Ventrus Biosciences, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders, primarily hemorrhoidal disease, anal fissures, and fecal incontinence. It is developing three late-stage product candidates, including Iferanserin ointment (VEN 309) for the topical treatment of symptomatic internal hemorrhoids; Diltiazem cream (VEN 307), a topical treatment for the relief of pain associated with anal fissures; and Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis, an FDA orphan indication. The company was formerly known as South Island Biosciences, Inc.

5) Impax Laboratories Inc. (NASDAQ:IPXL)

Sector:Healthcare
Industry:Drug Manufacturers - Major
Market Cap:$1.47B
Beta:0.24

Impax Laboratories Inc. has a Debt/Equity Ratio of 0.00 and Long Term Debt/Equity Ratio of 0.00 and Analysts' Rating of 2.50. The short interest was 5.30% as of 05/12/2012. Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products. The company operates in two divisions, Global Pharmaceuticals and Impax Pharmaceuticals. The Global Pharmaceuticals division develops, manufactures, sells, and distributes generic pharmaceutical products.

6) Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)

Sector:Healthcare
Industry:Drug Manufacturers - Major
Market Cap:$151.77M
Beta:1.04

Astex Pharmaceuticals, Inc. has a Debt/Equity Ratio of 0.00 and Long Term Debt/Equity Ratio of 0.00 and Analysts' Rating of 1.50. The short interest was 3.94% as of 05/12/2012. Astex Pharmaceuticals, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics with a focus on oncology and hematology. It develops novel small molecule therapeutics using its fragment-based drug discovery platform, Pyramid. The company offers Dacogen (decitabine) for injection, a DNA hypomethylating agent for the treatment of myelodysplastic syndromes.

*Company profiles were sourced from Finviz. Financial data was sourced from Google Finance and Yahoo Finance.

Source: 6 Low Debt Pharmaceutical Stocks Rated Buy Or Better